Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zomedica Pharmaceuticals Corp (ZOM)

Zomedica Pharmaceuticals Corp (ZOM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 95,349
  • Shares Outstanding, K 979,950
  • Annual Sales, $ 25,190 K
  • Annual Income, $ -34,530 K
  • EBIT $ -54 M
  • EBITDA $ -50 M
  • 60-Month Beta 1.15
  • Price/Sales 3.57
  • Price/Cash Flow N/A
  • Price/Book 0.47
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.03
  • Most Recent Earnings $-0.01 on 11/07/24
  • Next Earnings Date 03/13/25
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical Instruments

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.01
  • Number of Estimates 1
  • High Estimate -0.01
  • Low Estimate -0.01
  • Prior Year -0.01
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0920 +5.76%
on 03/04/25
0.1228 -20.77%
on 02/05/25
-0.0240 (-19.79%)
since 02/04/25
3-Month
0.0920 +5.76%
on 03/04/25
0.1580 -38.42%
on 01/03/25
-0.0321 (-24.81%)
since 12/04/24
52-Week
0.0920 +5.76%
on 03/04/25
0.1952 -50.15%
on 05/16/24
-0.0411 (-29.70%)
since 03/04/24

Most Recent Stories

More News
Zomedica Corp. Announces Transition to OTCQB Venture Market

Zomedica's ticker symbol will change to ZOMDF

ZOM : 0.0973 (-0.21%)
Zomedica to Report Fourth Quarter and Full Year 2024 Financial Results with a Business Update on March 13th at 4:30 p.m. ET

ANN ARBOR, MI / ACCESS Newswire / February 26, 2025 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products...

ZOM : 0.0973 (-0.21%)
Zomedica Improves Efficiency and Cuts Costs by Moving to New Headquarters

Relocation to More Efficient Space Supports Growth While Reducing Overhead by Over $200,000 Annually

ZOM : 0.0973 (-0.21%)
Zomedica Launches the TRUFORMA(R) Enhanced Endogenous ACTH Assay to aid in Equine PPID Diagnosis

Zomedica continues to redefine what is possible in point of care diagnostics with the TRUFORMA biosensor platform

ZOM : 0.0973 (-0.21%)
Zomedica Announces License & Supply Agreement with Cresilon Inc. to Market and Sell Vetigel(R) Hemostatic Gel in the Animal Health Market

License Agreement Expands Zomedica's Portfolio with Revolutionary Hemostatic Technology

ZOM : 0.0973 (-0.21%)
Zomedica Launches Two New Quantitative Assays on the TRUFORMA(R) Platform: Canine NT-proBNP and Progesterone

With the addition of these two new assay launches, Zomedica has added 8 new assays in the past 18 months to the rapidly growing TRUFORMA Platform

ZOM : 0.0973 (-0.21%)
Zomedica Appoints Scott A. Jordan Executive Vice President, Finance & Chief Financial Officer

Seasoned executive brings a broad skill set to Zomedica's leadership team

ZOM : 0.0973 (-0.21%)
Zomedica to Present at the NobleCon20 Twentieth Annual Emerging Growth Equity Conference December 4, 2024

ANN ARBOR, MI / ACCESSWIRE / November 27, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products...

ZOM : 0.0973 (-0.21%)
Zomedica, Inc. to Present at the LD Micro Main Event XVI

Presentation on Tuesday, October 3rd at 1:00 PM PTAnn Arbor, Michigan--(Newsfile Corp. - September 27, 2023) - Zomedica Corp. (NYSE American: ZOM) (the "Company") announced today that the Company is scheduled...

ZOM : 0.0973 (-0.21%)
Why Shares of Zomedica Were Zooming Monday

Investors bought back into the stock after it fell to its lowest point in two months.

ZOM : 0.0973 (-0.21%)

Business Summary

Zomedica Corp. is a veterinary health company. It creates products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica Corp., formerly known as Zomedica Pharmaceuticals Corp., is based in Ann Arbor, Michigan.

See More

Key Turning Points

3rd Resistance Point 0.1044
2nd Resistance Point 0.1008
1st Resistance Point 0.0991
Last Price 0.0973
1st Support Level 0.0938
2nd Support Level 0.0902
3rd Support Level 0.0885

See More

52-Week High 0.1952
Fibonacci 61.8% 0.1558
Fibonacci 50% 0.1436
Fibonacci 38.2% 0.1314
Last Price 0.0973
52-Week Low 0.0920

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar